The predictive value of lipid markers in vascular disease

Current Pharmaceutical Design

Volumn 11, Issue 17, 2005, Pages 2209-2224

  Milionis, H J ^a   Daskalopoulou, S S ^b   Elisaf, M ^a   Mikhailidis, D P ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Apoplipoproteins; Coronary heart disease; High density lipoprotein cholesterol; Lipid lowering drugs; Lipids; Low density lipoprotein cholesterol; Total cholesterol; Triglycerides

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE; ATORVASTATIN; BEZAFIBRATE; BILE ACID; CERIVASTATIN; CLOPIDOGREL; COLESTYRAMINE; ETC 216; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL PAIN; APHERESIS; ATHEROGENESIS; ATHEROSCLEROSIS; BLEEDING; BLOATING; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; DIET THERAPY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG COMPETITION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; FLATULENCE; FLUSHING; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEMOSTASIS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INFLAMMATION; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; LIPID METABOLISM; LIVER TOXICITY; MAXIMUM PERMISSIBLE DOSE; META ANALYSIS; MORBIDITY; MORTALITY; MYOPATHY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PARTICLE SIZE; PATHOGENESIS; PEPTIC ULCER; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; SMOKING; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; HUMANS; LIPIDS; PREDICTIVE VALUE OF TESTS; VASCULAR DISEASES;

EID: 21044437541     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612054367409     Document Type: Review

References (229)

1. Cooper R, Cutler J, Desvigne-Nickens P, Fortmarm SP, Friedman L, Havlik R, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: Findings of the National Conference on Cardiovascular Disease Prevention. Circulation 2000; 102: 3137-47.
2. Genest JJ Jr, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992; 85: 2025-33.
3. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152: 1490-500.
4. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991; 303: 276-82.
5. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
7. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-7.
8. Wong ND, Wilson PW, Kannel WB. Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. Ann Intern Med 1991; 115: 687-93.
9. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 85: 37-45.
10. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992; 70: 733-7.
11. Mikhailidis DP, Wierzbicki AS. HDL-cholesterol and the treatment of coronary heart disease: contrasting effects of atorvastatin and simvastatin. Curr Med Res Opin 2000; 16: 139-146.
12. Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998; 19 (Suppl A): A2-11.
13. Austin MA. Plasma triglyceride as a risk factor for cardiovascular disease. Can J Cardiol 1998; 14 (Suppl B): 1411-1713.
14. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoptotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-9.
15. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9.
16. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22.
17. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial -- Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
18. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18: 220-8.
19. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antilaypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998-3007.
20. Pasternak RC: The ALLHAT lipid lowering trial - less is less. JAMA 2002; 288: 3042-4.
21. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
22. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316, 099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152: 56-64.
23. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-30.
24. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071-80.
25. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Comparison of Intensive and Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med 2004; 350: 1495-504.
26. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998; 97: 946-52.
27. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.
28. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation 1999; 99: 1165-72.
29. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
30. De Backer G, Ambrosioni E, Borch-Johnsen, Brotons C, Citkova R, Dallongeville J, et al. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601-10.
31. UK HDL-C Consensus Group. Role of fibrates in reducing coronary risk: a UK Consensus. Curr Med Res Opin 2004; 20: 241-7.
32. Law MR, Wald NJ, Thompson SG. Serum cholesterol reduction and health: by how much and how quickly is the risk of ischaemic heart disease lowered? BMJ 1994; 308: 367-72.
33. Wald NJ, Law MR. Serum cholesterol and ischaemic heart disease. Atherosclerosis 1995; 118 (suppl): S1-S5.
34. Law MP, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423-27.
35. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419-24. Erratum in: BMJ 2003; 327: 586.
36. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular proteclive effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 2001; 104: 2376-83.
37. Wierzbicki AS, Mikhailidis DP. Beyond LDL-C--the importance of raising HDL-C. Curr Med Res Opin 2002; 18: 36-44.
38. Benoit P, Emmanuel F, Caillaud JM, Bassinet L, Castro G, Gallix P, et al. Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. Circulation 1999; 99: 105-10.
39. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E, Rader DJ. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 1999; 100: 1816-22.
40. Sacks FM; Expert Group on HDL Cholesterol. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002; 90: 139-43.
41. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15.
42. Castelli WP. Cardiovascular disease and multifactorial risk: Challenge of the 1980s. Am Heart J 1983; 106: 1191-200.
43. Tall AR. Plasma high density lipoproteins: Metabolism and relationship to atherogenesis. J Clin Invest 1990; 86: 379-84.
44. Frick MH, Syvänne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, et al., for the Lopid Coronary Angiography Trial (LOCAT) Study Group. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation 1997; 96: 2137-43.
45. Vakkilainen J, Steiner G, Ansquer JC, Aubin F, Rattier S, Foucher C, et al., DAIS Group. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003; 107: 1733-7.
46. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-64.
47. Lipid Research Clinics Program: The Lipid Research Clinic Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-74.
48. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-98.
49. Barter PJ, Rye K-A. High density lipoproteins and coronary heart disease. Atherosclerosis 1996; 121: 1-12.
50. Vega GL, Grundy SM. Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. Curr Opin Lipidol 1996: 7: 209-16.
51. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al., for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-8.
52. The Bezafibrate Infarction Prevention (BIP) Study Group. Secondary prevention by raising HDL-cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000; 102: 21-7.
53. Rizos E, Mikhailidis DP. Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials. Int J Cardiol 2002; 82: 199-207.
54. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269: 3015-23.
55. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290: 2292-300.
56. Silveira A. Postprandial triglycerides and blood coagulation. Exp Clin Endocrinol Diabetes 2001; 109: S527-32.
57. Davignon J, Cohn JS. Triglycerides: a risk factor for coronary heart disease. Atherosclerosis 1996; 124 (suppl): S57-64.
58. Miller M. Is hypertriglyceridaemia an independent risk factor for coronary heart disease? The epidemiological evidence. Eur Heart J 1998; 19 (Suppl H): H18-22.
59. Miller M, Seidler A, Moalemi A, Pearson TA. Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study. J Am Coll Cardiol 1998; 31: 1252-7.
60. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276: 882-8.
61. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998; 97: 1029-36.
62. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347: 849-53.
63. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223: 405-18.
64. Frohlich J, Steiner G. Dyslipidaemia and coagulation defects of insulin resistance. Int J Clin Pract Suppl 2000; 113: 14-22.
65. Avins AL, Neuhaus JM. Do triglycerides provide meaningful information about heart disease risk? Arch Intern Med 2000; 160: 1937-44.
66. Patsell JR, Miesenbock G, Hopferwieser T, Muhlberger V, Knapp E, Dunn JK, et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 1992; 12: 1336-45.
67. Kolovou G, Daskalova D, Mikhailidis DP. Apolipoprotein E polymorphism and atherosclerosis. Angiology 2003; 54: 59-71.
68. Kolovou GD, Anagnostopoulou KK, Pilatis ND, Iraklianou S, Hoursalas IS, Liberi S, et al. Heterozygote men with Familial Hypercholesterolaemia (FH) may have an Abnormal Triglyceride Response Postprandially. Evidence for another predictor of vascular risk in FH. Int J Clin Pract 2004; in press.
69. Kolovou G, Daskalova D, Anagnostopoulou K, Hoursalas I, Voudris V, Mikhailidis DP, et al. Postprandial hypertriglyceridaemia in patients with Tangier disease. J Clin Pathol 2003; 56: 937-41.
70. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: Predicting risks by levels and ratios. Ann Intern Med 1994; 121: 641-7.
71. Wallis EJ, Ramsay LE, Ul Haq I, Ghahramani P, Jackson PR, Rowland-Yeo K, et al. Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. BMJ 2000; 320: 671-6.
72. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001; 161: 1413-9.
73. Ballantyne CM, Andrews TC, Hsia JA, Kramer JH, Shear C. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol 2001; 88: 265-9.
74. Skalen K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Innerarity TL, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002; 417: 750-4.
75. Wang M, Briggs MR. HDL: the metabolism, function, and therapeutic importance. Chem Rev 2004; 104: 119-37.
76. Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 1996; 94: 273-8.
77. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-33.
78. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, et al. Atherosclerosis Risk in Communities Study Group. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subtractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001; 104: 1108-13.
79. Srinivasan SR, Berenson GS. Apolipoproteins B and A-I as predictors of risk of coronary artery disease. Lancet 2001; 358: 2012-3.
80. Kostner KM, Kostner GM. Lipoprotein (a): still an enigma? Curr Opin Lipidol 2002; 13: 391-6.
81. Milionis HJ, Elisaf MS, Mikhailidis DP. The effects of lipid-regulating therapy on haemostatic parameters. Curr Pharm Des 2003; 9: 2425-43.
82. Milionis HJ, Mikhailidis DP, Winder AF. Platelets and lipoprotein (a): a brief review of their role in the pathogenesis of atherothrombosis. Platelets 1999; 10: 277-84.
83. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994; 271: 999-1003.
84. Durrington PN, Ishola M, Hunt L, Arrol S, Bhatnagar D. Apolipoproteins (a), AI, and B and parental history in men with early onset ischaemic heart disease. Lancet 1988; 1: 1070-3.
85. Genest J Jr, McNamara JR, Ordovas JM, Jenner JL, Silberman SR, Anderson KM, et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992; 19: 792-802.
86. van Kooten F, van Krimpen J, Dippel DW, Hoogerbrugge N, Koudstaal PJ. Lipoprotein(a) in patients with acute cerebral ischemia. Stroke 1996; 27: 1231-5.
87. Barbir M, Kushwaha S, Hunt B, Macken A, Thompson GR, Mitchell A, et al. Lipoprotein(a) and accelerated coronary artery disease in cardiac transplant recipients. Lancet 1992; 340: 1500-2.
88. Orth-Gomer K, Mittleman MA, Schenck-Gustafsson K, Wamala SP, Eriksson M, Belkic K, et al. Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation 1997; 95: 329-34.
89. Cheshire NJW, Wolfe JHN, Barradas MA, Charribler AW, Mikhailidis DP. Smoking and plasma fibrinogen, lipoprotein (a) and serotonin are markers for postoperative infrainguinal graft stenosis. Eur J Vasc Endovasc Surg 1996; 11: 479-86.
90. Cantin B, Gagnon F, Moorjani S, Despres JP, Lamarche B, Lupien PJ, et al. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol 1998; 31: 519-25.
91. Von Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 2001; 37: 434-9.
92. Evans RW, Shpilberg O, Shaten BJ, Ali S, Kamboh MI, Kuller LH. Prospective association of lipoprotein(a) concentrations and apo(a) size with coronary heart disease among men in the Multiple Risk Factor Intervention Trial. J Clin Epidemiol 2001; 54: 51-7.
93. Ridker PM, Hennekens CA, Stampfer MJ. A prospective study of Lp(a) and the risk of myocardial infarction. JAMA 1993; 270: 2195-9.
94. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993; 270: 2195-9.
95. Ridker PM, Stampfer MJ, Hennekens CH. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 1995; 273: 1269-73.
96. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Manttari M, Manninen V, et al. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991; 89: 59-67.
97. Moliterno DJ, Jokinen EV, Miserez AR, Lange RA, Willard JE, Boerwinkle E, et al. No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans. Arterioscler Thromb Vasc Biol 1995; 15: 850-5.
98. Kronenberg F, Trenkwalder E, Dieplinger H, Utermann G. Lipoprotein(a) in stored plasma samples and the ravages of time. Why epidemiological studies might fail. Arterioscler Thromb Vasc Biol 1996; 16: 1568-72.
99. Albers JJ, Marcovina SM. Lipoprotein(a) quantification: comparison of methods and strategies for standardization. Curr Opin Lipidol 1994; 5: 417-21.
100. Stein JH, Rosenson RS. Lipoprotein Lp(a) excess and coronary heart disease. Arch Intern Med 1997; 157: 1170-6.
101. Harjai KJ. Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen. Ann Intern Med 1999; 131: 376-86.
102. Milionis HJ, Winder AF, Mikhailidis DP. Lipoprotein (a) and stroke. J Clin Pathol 2000; 53: 487-96.
103. Prelevic GM, Kwong P, Byrne DJ, Jagroop IA, Ginsburg J, Mikhailidis DP. A cross-sectional study of the effects of hormon replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril 2002; 77: 945-51.
104. Stojanovic ND, Kwong P, Byrne DJ, Arnold A, Jagroop IA, Nair D, et al. The effects of transdermal estradiol alone or with cyclical dydrogesterone on markers of cardiovascular disease risk in postmenopausal women with type 2 diabetes: a pilot study. Angiology 2003; 54: 391-9.
105. Elisaf M, Bairaktari E, Nicolaides C, Fountzilas G, Tzallas C, Siamopoulos K, et al. The beneficial effect of tamoxifen on serum lipoprotein-A levels: an additional anti-atherogenic property. Anticancer Res 1996; 16: 2725-8.
106. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995; 274: 1771-4.
107. 55 genotype. Arterioscler Thromb Vasc Biol 2000; 20: 2441-7.
108. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, et al. Paraoxonase status in coronary heart disease - are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001; 21: 1451-7.
109. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, et al. Low paraoxonase activity predicts coronary events in the Caerphilly prospective study. Circulation 2003; 107: 2775-9.
110. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152-4.
111. Curtiss LK, Boisvert WA. Apolipoprotein E and atherosclerosis. Curr Opin Lipidol 2000; 11: 243-51.
112. Utermann G, Kindermann I, Kaffarnik H, Steinmetz A. Apolipoprotein E phenotypes and hyperlipidemia. Hum Genet 1984; 65: 232-6.
113. Maitland-van der Zee AH, Klungei OH, Stricker BH, Monique Verschuren WM, Kastelein JJ, Leufkens HG, et al. Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. Atherosclerosis 2002; 163: 213-22.
114. Mahley RW, Huang Y. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol 1999; 10: 207-17.
115. Hagberg JM, Wilund KR, Ferrell RE. APO E gene and gene-environment effects on plasma lipoprotein-lipid levels. Physiol Genomics 2000; 4: 101-8.
116. Liberopoulos E, Karabina SA, Tselepis A, Bairaktari E, Nicolaides C, Pavlidis N, et al. Are the effects of tamoxifen on the serum lipid profile modified by apolipoprotein E phenotypes? Oncology 2002; 62: 115-20.
117. Utermann G, Hees M, Steinmetz A. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature 1977; 269: 604-7.
118. Wilson PWF, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein F alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA 1994; 272: 1666-71.
119. McCarron MO, Delong D, Alberts MJ. APOE genotype as a risk factor for ischemic cerebrovascular disease. A meta-analysis. Neurology 1999; 53: 1308-11.
120. Hoshino T, Kamino K, Matsumoto M. Gene dose effect of the APOE-epsilon4 allele on plasma HDL cholesterol level in patients with Alzheimer's disease. Neurobiol Aging 2002; 23: 41-5.
121. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260: 1917-21.
122. Coresh J, Kwiterovich PO Jr. Small dense low-density lipoprotein particles and coronary heart disease risk: a clear association with uncertain implications. JAMA 1996; 276: 914-5.
123. Sevanian A, Hwang J, Hodis H, Cazzolato G, Avogaro P, Bittolo-Bon G. Contribution of an in vivo oxidized LDL to LDL oxidation and its association with dense LDL subpopulations. Arterioscler Thromb Vasc Biol 1996; 16: 784-93.
124. Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 1993; 92: 141-6.
125. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82: 495-506.
126. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996; 276: 875-81.
127. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997; 80: 106-7.
128. Stein E, Sprecher D, Allenby KS, Tosiello RL, Whalen E, Ripa SR. Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia. J Cardiovasc Pharmacol Ther 1997; 2: 7-16.
129. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) Am J Cardiol 1998; 81: 582-7.
130. McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW; STELLAR Study Group. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003; 19: 689-98.
131. ones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, sirrivastatin. and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92: 152-60.
132. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340-6.
133. Crouse JR III, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997; 157: 1305-10.
134. Mohler ER, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003; 108: 1481-6.
135. McDermott MM, Guralnik JM, Greenland P, Pearce WH, Criqui MH, Liu K, et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 2003; 107: 757-61.
136. Mondillo S, Ballo P, Barbati R, Guerrini F, Ammaturo T, Agricola E, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 2003; 114: 359-64.
137. Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 2002; 325: 1139-41.
138. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, et al., for the Atorvastatin versus Revascularization Treatment Investigators. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341: 70-6.
139. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al., for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled trial. JAMA 2001; 285: 1711-8.
140. Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ III, Jones PH, West MS, et al., for the LCAS Investigators. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997; 80: 278-86.
141. Serruys PW, De Feyter PJ, Benghozi R, Hugenholtz PG, Lesaffre E. The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controllcd, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease. Int J Cardiovasc Intervent 2001; 4: 165-72.
142. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, et al. Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024-31.
143. Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003; 171: 1-13.
144. Milionis HJ, Elisaf MS, Mikhailidis DP. Treatment of dyslipidaemias in patients with established vascular disease: a review of the fibrates. Curr Med Res Opin 2000; 16: 21-32.
145. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 2002; 18: 269-76.
146. Dierkes J, Westphal S, Luley C. The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. Expert Opin Drug Saf 2004; 3: 101-11.
147. Wierzbicki AS, Mikhailidis DP, Wray R, Schacter M, Cramb R, Simpson WG, et al. Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr Med Res Opin 2003; 19: 155-68.
148. Aldridge MA, Ito MK. Colesevelam hydrochloride: a novel bile acid-binding resin. Ann Pharmacother 2001; 35: 898-907.
149. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 2004; 164: 697-705.
150. Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol 1998; 82 (12A): 29U-34U; discussion 39U-41U.
151. Capuzzi DM, Guyton JR, Morgan JM, Goldberg AC, Kreisberg RA, Brusco OA, et al. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 1998; 82 (12A): 74U-81U; discussion 85U-86U.
152. Stamler J. The coronary drug project--findings with regard to estrogen, dextrothyroxine, clofibrate and niacin. Adv Exp Med Biol 1977; 82: 52-75.
153. Wang DQ. New concepts of mechanisms of intestinal cholesterol absorption. Ann Hepatol 2003; 2: 113-21.
154. Sager PT, Melani L, Lipka L, Strony J, Yang B, Suresh R, et al. Ezetimibe Study Group. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003; 92: 1414-8.
155. Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, et al. Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107: 2409-15.
156. Davidson MH. Ezetimibe: a novel option for lowering cholesterol. Expert Rev Cardiovasc Ther 2003; 1: 11-21.
157. Melani L, Mills R, Hassman D, Lipetz R, Lipka L, LeBeaut A, et al. Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003; 24: 717-28.
158. Kerzner B, Corbelli J, Sharp S, Lipka LJ, Melani L, LeBeaut A, et al. Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003; 91: 418-24.
159. Gagne C, Gaudet D, Bruckert E; Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002; 105: 2469-75.
160. EASE Trial: Ezetimibe Add-on to Statin for Effectiveness Trial. Presented at the American College of Cardiology Annual Scientific Sessions 2004; New Orleans, Louisiana: March 7-10. http://www.cardiosource.com/webfiles/editorial/cardio/meetings/ acc04_rapidweds.htm
161. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99: 779-85.
162. Mata Lopez P, Ortega RM. Omega-3 fatty acids in the prevention and control of cardiovascular disease. Eur J Clin Nutr 2003; 57 (Suppl 1): S22-5.
163. Leaf A, Kang JX, Xiao YF, Billman GE. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation 2003; 107: 2646-52.
164. Leaf A, Xiao YF, Kang JX, Billman GE. Prevention of sudden cardiac death by n-3 polyunsaturated fatty acids. Pharmacol Ther 2003; 98: 355-77.
165. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 poly-unsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354: 447-55.
166. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet 1989; 2: 757-61.
167. Hu FB, Bronner L, Willett WC, Stampfor MJ, Rexrode KM, Albert CM, et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 2002; 287: 1815-21.
168. Mozaffarian D, Lemaitre RN, Kuller LH, Burke GL, Tracy RP, Siscovick DS; Cardiovascular Health Study. Cardiac benefits of fish consumption may depend on the type of fish meal consumed: the Cardiovascular Health Study. Circulation 2003; 107: 1372-7.
169. Lemaitre RN, King IB, Mozaffarian D, Kuller LH, Tracy RP, Siscovick DS. n-3 Polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: the Cardiovascular Health Study. Am J Clin Nutr 2003; 77: 319-25.
170. Stegmayr B, Lalau JD, Johnson O. In face of the increasing efficacy of lipid-lowering therapy, is there still a place for LDL-apheresis? Transfus Apheresis Sci 2004; 30: 213-20.
171. Mikhailidis DP, Ganotakis ES, Spyropoulos KA, Jagroop IA, Byrne DJ, Winder AF. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice. Int Angiol 1998; 17: 225-33.
172. Branchi A, Rovellini A, Sommariva D, Gugliandolo AG, Fasoli A. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb Haemost 1993; 70: 241-3.
173. Tsimihodimos V, Kostoula A, Kakafika A, Bairaktari E, Tselepis AD, Mikhailidis DP, et al. Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values. J Cardiovasc Pharmacol Ther 2004; 9: 27-33.
174. Rizos E, Bairaktari E, Ganotakis E, Tsimihodimos V, Mikhailidis DP, Elisaf M. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. J Cardiovasc Pharmacol Ther 2002; 7: 219-26.
175. Goudevenos JA, Bairaktari ET, Chatzidimou KG, Milionis HJ, Mikhailidis DP, Elisaf MS. The effect of atorvastatin on serum lipids, lipoprotein (a) and plasma fibrinogen levels in primary dyslipidaemia - a pilot study involving serial sampling. Curr Med Res Opin 2000; 16: 269-75.
176. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003; 19: 540-56.
177. Rosenson RS. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. Am J Cardiovasc Drugs 2001; 1: 411-20.
178. Watts GF, Dimmitt SB. Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr Opin Lipidol 1999; 10: 561-74.
179. Mathur S, Barradas MA, Mikhailidis DP, Dandona P. The effect of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: a pilot study. Diab Res 1990; 14: 133-138.
180. Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol 2003; 92 (4B): 17K-22K.
181. Ridker PM. Connecting the role of C-reactive protein and statins in cardiovascular disease. Clin Cardiol 2003; 26 (4 Suppl 3): III39-44.
182. Wang TD, Chen WJ, Lin JW, Cheng CC, Chen MF, Lee YT. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 2003; 170: 315-23.
183. Athyros VG, Elisaf M, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al. GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004; 43: 589-99.
184. Elisaf M, Mikhailidis DP. Statins and renal function. Angiology 2002; 53: 493-502.
185. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease: A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. J Clin Pathol 2004; 57: 728-34.
186. Rahman M, Brown CD, Coresh J, Davis BR, Eckfeldt JH, Kopyt N, et al. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Arch Intern Med 2004; 164: 969-76.
187. Bursztyn M, Motro M, Grossman E, Shemesh J. Accelerated coronary artery calcification in mildly reduced renal function of high-risk hypertensives: a 3-year prospective observation. J Hypertens 2003; 21: 1953-9.
188. Daskalopoulou SS, Athyros VG, Elisaf M, Mikhailidis DP. Uric acid levels and vascular disease. Curr Med Res Opin 2004; 20: 951-4.
189. Hoieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, et al. LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041-9.
190. Daskalopoulou SS, Athyros VG, Elisaf M, Mikhailidis DP. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 66: 1714-5.
191. Youssef F, Gupta P, Seifalian AM, Myint F, Mikhailidis DP, Hamilton G. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology 2004; 55: 53-62.
192. Buller CE, Nogareda JG, Ramanathan K, Ricci DR, Djurdjev O, Tinckam KJ, et al. The profile of cardiac patients with renal artery stenosis. J Am Coll Cardiol 2004; 43: 1606-13.
193. Gale CR, Ashurst H, Phillips NJ, Moat SJ, Bonham JR, Martyn CN. Renal function, plasma homocysteine and carotid atherosclerosis in elderly people. Atherosclerosis 2001; 154: 141-6.
194. Papadakis JA, Milionis HJ, Press M, Mikhailidis DP. Treating dyslipidaemia in non-insulin-dependent diabetes mellitus - a special reference to statins. J Diabetes Complications 2001; 15: 211-26.
195. Mayer O Jr, SImon J, Holubec L, Pikner R, Vobrubova II, Trefil L. Fibrate treatment and prevalence risk of mild hyperhomocysteinaemia in clinical coronary heart disease patients. Eur J Cardiovasc Prev Rehabil 2004; 11: 244-9.
196. Tsimihodimos V, Miltiadous G, Bairaktari E, Elisaf M. Possible mechanisms of the fibrate-induced increase in serum creatinine. Clin Nephrol 2002; 57: 407-8.
197. Wierzbicki AS. Lipid lowering: another method of reducing blood pressure? J Hum Hypertens 2002; 16: 753-60.
198. Rizos E, Mikhailidis DP. Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention? Cardiovasc Res 2001; 52: 199-207.
199. Papadakis JA, Mikhailidis DP, Winder AF. Lipids and stroke: neglect of a useful preventive measure? Cardiovasc Res 1998; 40: 265-71.
200. Cheng KS, Mikhailidis DP, Hamilton G, Seifalian AM. A review of the carotid and femoral intima-media thickness as all indicator of the presence of peripheral vascular disease and cardiovascular risk factors. Cardiovasc Res 2002; 54: 528-38.
201. Tsiara S, Plisaf M, Mikhailidis DP. Influence of smoking on predictors of vascular disease. Angiology 2003; 54: 507-30.
202. Aghdassi E, Allard JP. Breath alkanes as a marker of oxidative stress in different clinical conditions. Free Radic Biol Med 2000; 28: 880-6.
203. Milionis HJ, Rizos E, Mikhailidis DP. Smoking diminishes the beneficial effect of statins: observations from the landmark trials. Angiology 2001; 52: 575-87.
204. Daskalopoulou SS, Mikhailidis DP, Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology 2004;; 55: 589-612.
205. Papadakis JA, Ganotakis ES, Jagroop IA, Mikhailidis DP, Winder AF. Effect of hypertension, and its treatment, on lipid, lipoprotein (a), fibrinogen and bilirubin levels in patients referred for dyslipidaemia. Am J Hypertension 1999; 12: 673-81.
206. Ganotakis ES, Papadakis JA, Vrentzos GE, Mikhailidis DP. The effects of antihypertensive therapy on haemostatic parameters. Curr Pharm Design 2003; 9: 2445-64.
207. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
208. Butowski PF, Winder AF. Usual care dietary practice, achievement and implications for medication in the management of hypercholesterolaemia. Data from the U.K. Lipid Clinics Programme. Eur Heart J 1998; 19: 1328-33.
209. Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD, Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004; 109: 1335-8.
210. Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, et al. Clopidogrel for the Reduction of Events During Observation Investigators. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003; 108: 921-4.
211. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in famil ial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357: 577-81.
212. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002; 106: 2055-60.
213. Youssef F, Seifalian AM, Jagroop A, Myint F, Baker D. Mikhadidis DP, et al. The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT). Eur J Vasc Endovasc Surg 2002; 23: 358-64.
214. Brown BG, Morse J, Zhao XQ, Cheung M, Marino E, Albers JJ. Electron-beam tomography coronary calcium scores are superior to Framingham risk variables for predicting the measured proximal stenosis burden. Am J Cardiol 2001; 88: E23-6.
215. Allison MA, Wright CM. A comparison of HDL and LDL cholesterol for prevalent coronary calcification. Int J Cardiol 2004; 95: 55-60.
216. Achenbach S, Ropers D, Pohle K, Leber A, Thilo C, Knez A, et al. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation 2002; 106: 1077-82.
217. Raggi P, Callister TQ, Shaw LJ. Progression of Coronary Artery Calcium and Risk of First Myocardial Infarction in Patients Receiving Cholesterol-Lowering Therapy. Arterioscler Thromb Vasc Biol 2004; 24: 1272-7.
218. Boden WE, Pearson TA. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy. Am J Cardiol 2000; 85: 645-50.
219. Rosen RC, Fisher WA, Eardley I, Niederberger C, Nadel A, Sand M; Men's Attitudes to Life Events and Sexuality (MALES) Study. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004; 20: 607-17.
220. Shabbir M, Mikhailidis DP, Morgan RJ. Erectile dysfunction: an underdiagnosed condition associated with multiple risk factors. Curr Med Res Opin 2004; 20: 603-6.
221. Rizvi K, Hampson JP, Harvey JN. Do lipid-lowering drugs cause erectile dysfunction? A systematic review. Fam Pract 2002; 19: 95-8.
222. Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud KE, et al. Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 2004; 164: 146-52.
223. Yaturu S. Skeletal effects of statins. Endocr Pract 2003; 9: 315-20.
224. Baghdasarian SB, Jneid H, Hoogwerf BJ. Association of dyslipidemia and effects of statins on nonmacrovascular diseases. Clin Ther 2004; 26: 337-51.
225. Miller LJ, Chacko R. The role of cholesterol and statins in Alzheimer's disease. Ann Pharmacother 2004; 38: 91-8.
226. Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer's disease. Neuroepidemiology 2004; 23: 94-8.
227. Acosta J, Qin X, Halperin J. Complement and complement regulatory proteins as potential molecular targets for vascular diseases. Curr Pharm Design 2004; 10(2): 203-11.
228. Ishikawa K. Heme oxygenase-1 against vascular insufficiency: roles of atherosclerotic disorders. Curr Pharm Design 2003; 9(30): 2489-97.
229. Milionis HJ, Elisaf MS, Mikhailidis DP. The effects of lipid-regulating therapy on haemostatic parameters. Curr Pharm Design 2003; 9(29): 2425-43.